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Results: From September 2011 to December 2013, 80 
patients were enrolled and two patients withdrew consent, 
finally 78 patients included for analysis. There were 73 male 
and 5 female. There were 96.2% of them had 0-1 WHO ECOG. 
For the primary site, 23(29.5%) patients were oral cavity, 26 
(33.3%) patients were oropharynx, 24(30.8%) patients were 
hypopharynx, and 5 (6.4%) patients were larynx. Treatment 
compliance was well. There were 92.3% patients completed 
planned schedule. After the induction chemotherapy, the 
overall response rate were 92.3%, which included 37.2% 
complete response and 55.1% partial response, respectively. 
Only 2(2.6%) patients had stable disease and 1(1.3%) patient 
had progression disease. The response rate of oral cavity, 
oropharynx, hypopharynx, and larynx were 82.6%, 92.3%, 
100%, 100%, respectively. There were 47.4% grade 3 or 4 
neutropenia and 20.5% grade 3 anemia. Only 6 severe adverse 
event were report, including 4 febrile neutropenia with 
sepsis, one osteomyelitis, and one massive bleeding. 
 
Conclusion: This outpatient docetaxel-based neoadjuvant 
chemotherapy regimen is a effective regimen in locally 
advanced squamous cell carcinoma of head and neck. 
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Purpose or Objective: The goal of this study is was to 
evaluate the results of treatment of T1N0M0 glottic cancer 
with irradiation, with emphasis on the influence of time from 
diagnosis to the beginning of radiation therapy. 
 
Material and Methods: We performed the retrospective 
analysis of the group of 539 patients with T1N0M0 glottic 
cancer, treated with radiation therapy in the Center of 
Oncology in Cracow between years 1977 and 2004. In 481 
cases (89%) the tumor was limited to single vocal cord and in 
the remaining 58 involved both of them. Anterior commisure 
involvement was observed in 173 (32%) of the patients. 
According to the radiotherapy technique and fractionation 
scheldule, we have divided patients into three separate 
groups: I - two oblique fields, TD 60 Gy/24 - 277 patients 
(51%); II - two opposite fields, TD 60 Gy/30 - 160 (31%); III - 
one lateral photon-electron beam, TD 60 Gy/30 - 102 (19%). 
The average time from laryngeal biopsy to the beginning of 
radiotherapy was 56 days (range: 3 -145 days). The overall 
survival (OS) and disease- free survival (DFS) were calculated 
using the Kaplan - Meier method. Log - rank test was used to 
calculate differences between each groups, and the 
independent prognostic factors were selected by the Cox 
multiparameter analysis. 
 
Results: The 5-year OS and 10-year OS were 84% and 69%, 5- 
and 10-year DFS were 90% and 88%, and the 5- and 10-year LC 
rates were 89% and 87%, respectively. One- dimensional 
analysis revealed following prognostic factors for LC and DFS: 
tobbaco smoking, radiotherapy technique, and the anterior 
commisure involvement. The 5- and 10-year LC rates in the 
group of patients smoking less than 20 cigarettes a day were 
90% and 87%, compared to 76% and 70%, respectively, in the 
group smoking more than 20 cigarettes a day (p=0,01). 
Considering the RT technique, the lowest 5- and 10-year LC 
rates were observed in the group treated with opposite 
beams (80% and 78%, respectively), and the highest when the 
oblique fields were used - 91% and 88%, respectively 
(p=0,002). The tumor involvement of the anterior commisure 
decreased 5-year LC by 15% (92 to 77%), and 10- year LC rate 
by 19% (89 to 70%, respectively, p=0,000). The waiting time 
for the beginning of RT longer than 30 days from the biopsy 
was statistically significant poor prognostic factor for DFS and 
LC. 5- and 10- year LC rates in the group of patients who 
started RT during the period of 30 days from the biopsy were 
92% and 90%, respectively, and in the group which started 
treatment after that time, these LC rates were 84% and 82%, 
respectively (p=0,01). Tumor interior commisure involvement 
was proven to be an independent prognostic factor affecting 
DFS and LC. 
 
Conclusion:  
1. Radiation therapy is efficient method of treatment the 
T1N0M0 glottic cancer 
2. Prolonged time of waiting for the beginning of RT 
decreases the LC and DFS rates 
3. The tumor involvement of anterior laryngeal commisure 
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Purpose or Objective: The aim of the present study is to 
analyze clinical outcomes and toxicity in patients with 
locoregionally advanced head and neck carcinoma treated 
with concurrent hyperfractionated radiotherapy with 
Cetuximab and Carboplatin. 
 
Material and Methods: Forty-one patients (8 cases ST.III and 
33 cases ST.IV) were prospectively included in this study from 
September 2009 to November 2014. Radiotherapy consisted 
in hyperfractionated radiotherapy: 1.15-1.20 Gy/fraction, 
BID, 5 days/week during 7 weeks. The average dose 
administered was 80.2 Gy (79.2-80.5). Carboplatin was 
administered 5 mg/m2 before each fraction of radiotherapy. 
Cetuximab was administered 400 mg/m2 one week before 
hyperfractionated radiotherapy and then 250 mg/m2 weekly 
while radiotherapy. Seven patients were not evaluable for 
response (in 3 patients, Capecitabine was added to the 
treatment; in 1 patient nodal metastases came from a 
papillary thyroid carcinoma; 3 patients were not evaluable 
for response because 2 patients died within 30 days after 
treatment and 1 patient has not enough follow-up to be 
evaluated for response). 
 
Results: All but 2 of the 34 evaluable patients showed 
objective response (19 complete responses). The local 
relapse-free survival, cause specific survival, and overall 
survival was 58.7%, 57%, 49% at 5 years, respectively. Severe 
(GradeII/III) acneiform rash resulted predictive of Clinical 
Response (p=0,005), Local relapse (p=0,008), distant 
metastases (p=0,012) and tumour related dead free survival 
(p<0,0001). Severe (Grade III) acute cutaneous and mucosal 
toxicity was present in almost 60% of the cases.  
 
Conclusion: This protocol induces a high rate of clinical 
responses and excellent survival figures in patients 
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Purpose or Objective: The current standard of care for 
newly diagnosed papillary thyroid carcinoma invading the 
trachea is surgical resection followed by radioactive iodine 
therapy (RAI) and thyroid stimulating hormone suppression. 
However, the local recurrence rate is high. Several studies 
reported adjuvant external beam radiotherapy (EBRT) 
reduced the local recurrence. The benefit of adjuvant EBRT 
remains controversial. We evaluated the effect of adjuvant 
EBRT on local control in a single institution database. 
 
Material and Methods: Between May 2003 and October 2013, 
36 patients with locally advanced papillary thyroid carcinoma 
invading the trachea (pathologic stage T4) were treated with 
surgical resection. After surgery, 16 patients received 
adjuvant EBRT using intensity modulated radiation therapy 
followed by RAI, and 20 patients were treated with RAI 
alone. The age range was 36-87 years (median 64 years). 
EBRT doses ranged from 30-66 Gy (median 60 Gy). There was 
no statistically significant difference in terms of clinical 
characteristics between the EBRT and no EBRT groups. 
 
Results: Median follow up was 26.6 months (range, 16.5-40.1) 
in EBRT group, and 43.9 months (range, 13.9-117.6) in no 
EBRT group. There was no local or distant failure in EBRT 
group during the follow up. There were five local failures and 
one distant failure in no EBRT group. The two-year & five-
year local failure free survival rates were 95.0% and 49.8% in 
no EBRT group. There were acute grade 2 esophagitis (n=1) 
and grade 2 skin reaction (n=3). There were no grade 2 late 
complications in EBRT group. 
 
Conclusion: Adjuvant EBRT was found to be an effective 
treatment for local control in papillary thyroid carcinoma 
invading the trachea with tolerable complications, in a study 
at a single institution. Longer follow up will be required to 
demonstrate outcomes for tumor control and complications 
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Purpose or Objective: Locally advanced, high-risk cutaneous 
squamous cell carcinoma (CSCC) of the head and neck are 
typically aggressive and treated with combined modality 
therapy. These patients tend to be older, frail with multiple 
comorbidities which makes chemotherapy difficult to 
tolerate. Cetuximab is a monoclonal antibody against the 
EGFR receptor and has demonstrated activity in CSCC. We 
investigate the safety and efficacy of combined therapy in 
advanced, high risk CSCC with the addition of cetuximab. 
 
Material and Methods: Patients were identified with locally 
advanced CSCC with high risk or very high risk features who 
were treated with cetuximab and radiotherapy between 2006 
and 2013. A matched cohort over the same time period was 
identified who were treated with radiation. Propensity score 
analysis was performed with weighted factors including: 
Charlson Comorbidity Index score (age-adjusted), age. KPS, 
primary location, T and N stage, recurrent status, margin 
status, LVSI, PNI and grade. Overall survival, progression free 
survival and freedom from local or distant recurrence were 
evaluated with the Kaplan-Meier method for both the un-
adjusted and propensity score adjusted groups. Multivariate 
analysis was performed using cox proportional hazard models.  
Results: 29 patients were in the cetuximab and 39 in the 
control group. Median follow-up for alive patients was 30 
months. Patients in the cetuximab group were more likely to 
have advanced N stage, positive margins and recurrent 
disease. After propensity score matching the groups were 
well balanced. OS was not statistically significant between 
the two groups but depicted in Table 1 below there were 
approximately 20% more long term survivors in the cetuximab 
group after matching. Local control was 76% and 79% in the 
cetuximab and control groups, respectively. The rate of 
distant metastases was lower in the cetuximab group 6.8% 
versus 10%. The incidence of grade 2-3 toxicity was 41% in 
the cetuximab group. There was one grade 3 cetuximab 
acneiform rash, one grade 4 dysphagia and no grade 5 
toxicity.  
 
Table 1 Overall Survival Probabilities by year in both 




Conclusion: Although limited by small numbers, we found 
that there were more long-term survivors and less distant 
metastasis in the cetuximab group. This is the largest report 
of CSCC patients treated with cetuximab. In the absence of 
prospective data, we believe this data reveals that the 
addition of cetuximab is well tolerated and reveals signs of 
efficacy in this typically poor performing group of patients 
and should be pursued in clinical trials. 
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Purpose or Objective: Ki-67 index is used to assess cell 
proliferation during histopathological assessment of various 
tumours including high grade gliomas (HGG): Anaplastic 
astrocytoma, Anaplastic Oligodendroglioma and Glioblastoma 
Multiforme (GBM). We aimed to determine if there is a 
correlation between percentage staining of Ki-67 and overall 
survival in patients with HGG and determine a cut-point for 
percentage staining of Ki-67 that predicts for poorer survival. 
 
Material and Methods: Records of adult patients diagnosed 
with HGG on histopathological specimens examined at the 
Institute of Clinical Pathology and Medical Research at 
Westmead Hospital, NSW, between 1st of January 2002 and 
30th of July 2012 were identified. The specimens of these 
patients were examined for quantification of Ki-67 staining 
by two independent pathologists. Patient, disease, treatment 
and survival data were collected from hospital and cancer 
care service records. Descriptive statistical analyses were 
performed on the patient, disease and treatment data. 
Survival curves were constructed using Kaplan Meir methods. 
Using the minimum p value approach we obtained a cut-point 
for Ki-67 percentage staining that predicts for poorer 
survival. 
 
Results: Of the eligible 78 patients (median age = 57, range 
18 - 87) 46 (59 %) were males and 32 (41%) were females. 59 
(76%) patients were of ECOG performance status 0 -1. Seven 
patients had anaplastic astrocytoma or anaplastic 
